Furiex Pharmaceuticals (FURX) Narrows Q3 Loss
Tweet
Share
E-mailGet Alerts FURX Hot Sheet
Join SI Premium – FREE
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) reported Q3 loss of ($1.32), versus ($2.14) reported last year. Revenue for the quarter came in at $1.27 million, versus $288 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c
- Stantec (STN) Tops Q2 EPS by 47c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
